We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Read more
Bachem is ramping up new high-volume production and more automated operations to meet rising demand for complex medicines made from peptides and oligonucleotides, with long-term customer ties that could make revenue steadier over time. The big question is whether it can expand on schedule without cost overruns, currency swings, or pricing pressure eating into profits.Read more
Bachem helps drugmakers develop and make complex ingredients, but tougher rules, pricing pressure, and cheaper rivals could slow its growth and squeeze profits. The company is also spending heavily to expand capacity, and a demand slowdown or shift to other technologies could leave new sites underused.Read more
Bachem may be closer to a step-up in growth than most people expect as new manufacturing sites ramp faster and production gets more automated. The upside comes with real pressure points though, including big expansion spending, a narrow product focus, and the risk that rivals catch up or global supply chains get disrupted.Read more
No trending discussion available.
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
